Business World: Biogen Idec, Elan, & Tysabri (Natalizumab)
A fourth death may be tied to Biogen's MS drug[ ... Read the full article ... ]
Finding could be blow to marketplace hopes
By Jeffrey Krasner,
Boston Globe Staff
June 2, 2005
Biogen Idec Inc. has told the Food and Drug Administration that a fourth patient may have contracted a potentially deadly brain disease after being treated with the company's multiple sclerosis drug Tysabri.
Anthony H. Risser | neuroscience | neuropsychology | brain